Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

Luciano J. Costa; Thomas W. LeBlanc; Hans Tesch; Pieter Sonneveld; Ryan P. Kyle; Liliya Sinyavskaya; Patrick Hlavacek; Aster Meche; Jinma Ren; Alex Schepart; Didem Aydin; Guido Nador; Marco da Costa DiBonaventura

doi:10.2217/fon-2023-0995

Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P. Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco da Costa DiBonaventura^*

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

32 Downloads (Pure)

Abstract

Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physician's choice of treatment (PCT) for triple-class refractory multiple myeloma. MagnestisMM-3 eligibility criteria were applied to two USA-based oncology electronic health record databases, COTA and Flatiron Health (FH), to identify cohorts for this study (NCT05932290). Applied statistical techniques accounted for cohort imbalances. MagnetisMM-3 (BCMA-naive; n = 123) outcomes were compared with those from COTA (n = 239) and FH (n = 152). Elranatamab was associated with a significantly higher objective response rate (risk ratios, 1.88–2.25), significantly longer progression-free survival (hazard ratios [HRs], 0.37–0.57), and, across most analyses, significantly longer overall survival (HRs, 0.46–0.66) versus PCT. BCMA-naive patients who were treated with elranatamab exhibited significantly better outcomes than patients treated in real-world clinical practice.

Original language	English
Pages (from-to)	1175-1189
Number of pages	15
Journal	Future Oncology
Volume	20
Issue number	17
DOIs	https://doi.org/10.2217/fon-2023-0995
Publication status	Published - 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2023-0995Licence: CC BY-NC-ND

Elranatamab_efficacy_in_MagnetisMM-3_compared_with_real-world_control_arms_in_triple-class_refractory_multiple_myelomaFinal published version, 2.82 MBLicence: CC BY-NC-ND

Cite this

Costa, L. J., LeBlanc, T. W., Tesch, H., Sonneveld, P., Kyle, R. P., Sinyavskaya, L., Hlavacek, P., Meche, A., Ren, J., Schepart, A., Aydin, D., Nador, G., & DiBonaventura, M. D. C. (2024). Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncology, 20(17), 1175-1189. https://doi.org/10.2217/fon-2023-0995

@article{2a365418ce9b47b18ea0878bef383db3,

title = "Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma",

abstract = "Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physician's choice of treatment (PCT) for triple-class refractory multiple myeloma. MagnestisMM-3 eligibility criteria were applied to two USA-based oncology electronic health record databases, COTA and Flatiron Health (FH), to identify cohorts for this study (NCT05932290). Applied statistical techniques accounted for cohort imbalances. MagnetisMM-3 (BCMA-naive; n = 123) outcomes were compared with those from COTA (n = 239) and FH (n = 152). Elranatamab was associated with a significantly higher objective response rate (risk ratios, 1.88–2.25), significantly longer progression-free survival (hazard ratios [HRs], 0.37–0.57), and, across most analyses, significantly longer overall survival (HRs, 0.46–0.66) versus PCT. BCMA-naive patients who were treated with elranatamab exhibited significantly better outcomes than patients treated in real-world clinical practice.",

author = "Costa, \{Luciano J.\} and LeBlanc, \{Thomas W.\} and Hans Tesch and Pieter Sonneveld and Kyle, \{Ryan P.\} and Liliya Sinyavskaya and Patrick Hlavacek and Aster Meche and Jinma Ren and Alex Schepart and Didem Aydin and Guido Nador and DiBonaventura, \{Marco da Costa\}",

note = "Publisher Copyright: {\textcopyright} 2024 Pfizer.",

year = "2024",

doi = "10.2217/fon-2023-0995",

language = "English",

volume = "20",

pages = "1175--1189",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor \& Francis Ltd",

number = "17",

}

Costa, LJ, LeBlanc, TW, Tesch, H, Sonneveld, P, Kyle, RP, Sinyavskaya, L, Hlavacek, P, Meche, A, Ren, J, Schepart, A, Aydin, D, Nador, G & DiBonaventura, MDC 2024, 'Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma', Future Oncology, vol. 20, no. 17, pp. 1175-1189. https://doi.org/10.2217/fon-2023-0995

TY - JOUR

T1 - Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

AU - Costa, Luciano J.

AU - LeBlanc, Thomas W.

AU - Tesch, Hans

AU - Sonneveld, Pieter

AU - Kyle, Ryan P.

AU - Sinyavskaya, Liliya

AU - Hlavacek, Patrick

AU - Meche, Aster

AU - Ren, Jinma

AU - Schepart, Alex

AU - Aydin, Didem

AU - Nador, Guido

AU - DiBonaventura, Marco da Costa

PY - 2024

Y1 - 2024

N2 - Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physician's choice of treatment (PCT) for triple-class refractory multiple myeloma. MagnestisMM-3 eligibility criteria were applied to two USA-based oncology electronic health record databases, COTA and Flatiron Health (FH), to identify cohorts for this study (NCT05932290). Applied statistical techniques accounted for cohort imbalances. MagnetisMM-3 (BCMA-naive; n = 123) outcomes were compared with those from COTA (n = 239) and FH (n = 152). Elranatamab was associated with a significantly higher objective response rate (risk ratios, 1.88–2.25), significantly longer progression-free survival (hazard ratios [HRs], 0.37–0.57), and, across most analyses, significantly longer overall survival (HRs, 0.46–0.66) versus PCT. BCMA-naive patients who were treated with elranatamab exhibited significantly better outcomes than patients treated in real-world clinical practice.

AB - Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physician's choice of treatment (PCT) for triple-class refractory multiple myeloma. MagnestisMM-3 eligibility criteria were applied to two USA-based oncology electronic health record databases, COTA and Flatiron Health (FH), to identify cohorts for this study (NCT05932290). Applied statistical techniques accounted for cohort imbalances. MagnetisMM-3 (BCMA-naive; n = 123) outcomes were compared with those from COTA (n = 239) and FH (n = 152). Elranatamab was associated with a significantly higher objective response rate (risk ratios, 1.88–2.25), significantly longer progression-free survival (hazard ratios [HRs], 0.37–0.57), and, across most analyses, significantly longer overall survival (HRs, 0.46–0.66) versus PCT. BCMA-naive patients who were treated with elranatamab exhibited significantly better outcomes than patients treated in real-world clinical practice.

UR - https://www.scopus.com/pages/publications/85193405313

U2 - 10.2217/fon-2023-0995

DO - 10.2217/fon-2023-0995

M3 - Article

C2 - 38415370

AN - SCOPUS:85193405313

SN - 1479-6694

VL - 20

SP - 1175

EP - 1189

JO - Future Oncology

JF - Future Oncology

IS - 17

ER -

Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this